

DAFTAR PUSTAKA

1. Li H, Liu C, Xu Y, et al. Age-dependent changes in skeletal muscle mass and visceral fat area in a Chinese population. *Eur J Clin Nutr.* 2023;77(7):1042-1050. doi:10.1038/s41430-023-01251-1.
2. Lim S, Kim JH, Yoon JW, et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Sarcopenic Obesity Study (KSOS). *Diabetes Care.* 2010;33(7):1652-1654. doi:10.2337/dc09-2314.
3. Lai LL, Chen TM, Wong GL, Jeong J, Han S, Yang JD, et al. Incidence of metabolic dysfunction-associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study. *Liver Int.* 2024;44(5):1056-1068.
4. Rinella, M. E. *et al.* A multisociety Delphi consensus statement on new fatty liver disease nomenclature. *J. Hepatol.* **79**, 1542–1556 (2023).
5. Setiati S, D. N. Sarkopenia. *Buku Ajar Ilmu Penyakit Salam* **4th ed**, 466 (2015).
6. Cruz-Jentoft, A. J. *et al.* Sarcopenia: Revised European consensus on definition and diagnosis. *Age Ageing* **48**, 16–31 (2019).
7. Wang, Y. M. *et al.* Sarcopenia is associated with the presence of nonalcoholic fatty liver disease in Zhejiang Province, China: a cross-sectional observational study. *BMC Geriatr.* **21**, 1–9 (2021).
8. Nishikawa, H., Asai, A., Fukunishi, S., Nishiguchi, S. & Higuchi, K. Metabolic syndrome and sarcopenia. *Nutrients* **13**, 1–12 (2021).
9. Lee, H. J. *et al.* Association between Low Muscle Mass and Non-alcoholic Fatty Liver Disease Diagnosed Using Ultrasonography, Magnetic Resonance Imaging Derived Proton Density Fat Fraction, and Comprehensive NAFLD Score in Korea. *J. Prev. Med. Public Heal.* **54**, 412–421 (2021).
10. Koehler, E. M. *et al.* Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: Results from the Rotterdam study. *J. Hepatol.* **57**,

- 1305–1311 (2012).
11. Eslam, M. *et al.* A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J. Hepatol.* **73**, 202–209 (2020).
 12. Chen, L. K. *et al.* Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. *J. Am. Med. Dir. Assoc.* **21**, 300-307.e2 (2020).
 13. Dan, P., Sarkopenia, T. L., Dinakrisma, A. A., Setiati, P. S. & Epid, M. DI INDONESIA.
 14. Feng, Z. *et al.* The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations. *BMC Gastroenterol.* **24**, 1–11 (2024).
 15. Alferink, L. J. M. *et al.* Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution. *J. Bone Miner. Res.* **34**, 1254–1263 (2019).
 16. Li, X., He, J. & Sun, Q. The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis. *Clin. Nutr.* **43**, 2005–2016 (2024).
 17. Lee, S. B., Kwon, Y. J., Jung, D. H. & Kim, J. K. Association of Muscle Strength with Non-Alcoholic Fatty Liver Disease in Korean Adults. *Int. J. Environ. Res. Public Health* **19**, (2022).
 18. Lee, I., Cho, J., Park, J. & Kang, H. Association of hand-grip strength and non-alcoholic fatty liver disease index in older adults. *J. Exerc. Nutr. Biochem.* **22**, 62–68 (2018).
 19. Martinez, B. P. *et al.* Accuracy of the timed up and go test for predicting sarcopenia in elderly hospitalized patients. *Clinics* **70**, 369–372 (2015).
 20. Facts, O. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). *Obes. Facts* **2024**, 374–443 (2024).
 21. Singh, A., Buckholz, A., Kumar, S. & Newberry, C. Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic

- Dysfunction-Associated Steatotic Liver Disease (MASLD). *Nutrients* **16**, (2024).
22. Ganakumar, V., Halebidu, T., Goroshi, M. & Ghatnatti, V. Diagnosis and Management of MASLD: An Metabolic Perspective of a Multisystem Disease. *Int. J. Clin. Metab. Diabetes* (2024) doi:10.1177/30502071231220779.
 23. Alhinai, A., Patel, K., Fonseca, V. A. & Sebastiani, G. Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. *J. Diabetes Complications* **35**, 107978 (2021).
 24. Giovannini, S. *et al.* Sarcopenia: Diagnosis and management, state of the art and contribution of ultrasound. *J. Clin. Med.* **10**, (2021).
 25. Ackermans, L. L. G. C. *et al.* Screening, diagnosis and monitoring of sarcopenia: When to use which tool? *Clin. Nutr. ESPEN* **48**, 36–44 (2022).
 26. Nishikawa, H. *et al.* Screening tools for sarcopenia. *In Vivo (Brooklyn)*. **35**, 3001–3009 (2021).
 27. Beaudart, C. *et al.* Sarcopenia in daily practice: assessment and management. *BMC Geriatr.* **16**, 1–10 (2016).
 28. Tosato, M. *et al.* Measurement of muscle mass in sarcopenia: from imaging to biochemical markers. *Aging Clin. Exp. Res.* **29**, 19–27 (2017).
 29. Lee, K. *et al.* Recent issues on body composition imaging for sarcopenia evaluation. *Korean J. Radiol.* **20**, 205–217 (2019).
 30. De Fré, C. H. *et al.* Sarcopenia in patients with non-alcoholic fatty liver disease: is it a clinically significant entity? *Obes. Rev.* **20**, 353–363 (2019).
 31. Hong, H. C., Hwang, S. Y., Choi, H. Y., Yoo, H. J., Seo, J. A., Kim, S. G., ... & Kim, N. H. (2020). Relationship between sarcopenia and nonalcoholic fatty liver disease: The Korean Sarcopenic Obesity Study. *Hepatology*, 71(4), 1427–1437.
 32. Lee, Y. H., Jung, K. S., Kim, S. U., Yoon, H. J., Yun, Y. J., Lee, B. W., ... & Kim, H. C. (2020). Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008–2011). *Hepatology*, 72(4),

1160–1170

33. Peng, T. C., Wu, L. W., Chen, W. L., Liaw, F. Y., Chang, Y. W., & Kao, T. W. (2021). Nonalcoholic fatty liver disease and sarcopenia in a military population: A community-based cross-sectional study. *BMC Gastroenterology*, 21, 190.
34. Cruz-Jentoft, A. J., et al. (2019). Sarcopenia: Revised European consensus on definition and diagnosis. *Age and Ageing*, 48(1), 16–31
35. Yamamoto, K., Kitagawa, N., Kubo, Y., & Okura, T. (2022). Effects of resistance training on physical performance and inflammatory markers in elderly adults with sarcopenia: A randomized controlled trial. *Journal of Cachexia, Sarcopenia and Muscle*, 13(4), 2081–2089